Join our daily newsletter At The Bell to receive exclusive market insights
- Emyria (EMD) progresses its drug discovery and development of the company’s preclinical MDMA analogue medicine program with program partner UWA
- The partnership has created a third batch comprising of 19 novel MDMA analogues which have been characterised and sent for screening
- The design of the batch is led by Professor Matt Piggott and his team at UWA and was guided by the results received from the screening of the first two batches
- Managing Director Dr Michael Winlo says the company had identified three therapeutic areas to target following its initial screening results
- Shares in Emyria are down 4.55 per cent to close at 21 cents
Emyria (EMD) has progressed its drug discovery and development of its preclinical MDMA analogue medicine program with the University of Western Australia (UWA).
The company and UWA have created a third batch comprising of 19 novel MDMA analogues which have been characterised and sent for screening.
The design of the batch was led by Professor Matt Piggott and his team at UWA and was guided by the results received from the screening of the first two batches.
With the third batch, the library size of MDMA-like compounds is now over 125 with additional design and ongoing synthesis.
Professor Piggott said the results of the first rounds of screening informing subsequent analogue design is the critical feedback loop that drives drug discovery.
Emyria Managing Director Dr Michael Winlo said the company had identified three therapeutic areas to target following its initial screening results for the ongoing synthesis program and associated intellectual property strategy.
The areas include next-generation psychedelic-assisted therapeutics to help treat major mental health disorders, novel small molecule treatments for neurological disorders where selective receptor effects are desired and treatments for non-neurological disorders.
“We are strengthening Emyria’s IP portfolio and potential slate of proprietary drug candidates targeting major unmet needs,” Dr Winlo elaborated.
“Our preclinical program complements our advanced clinical programs and demonstrates the depth of our unique drug discovery and development opportunities and capabilities.”
Shares in Emyria were down 4.55 per cent to close at 21 cents.
